PDRN has gone from a specialist ingredient to something you can buy at almost any price point. A single Cosmetics Business launch round-up at the end of September found it in products from L'Oréal Paris, The Ordinary, Primark, Clinique and Dior. The Primark range starts at £2.50, and the Dior serum costs £72.
Read the small print on those launches, though, and the sourcing stories don't match. The Ordinary's version comes from fermentation with Lactobacillus rhamnosus. Primark's is derived from camellia flower, Clinique's is described as biotech-derived from cica, and several others just say "vegan" or "plant-derived."
That makes PDRN a useful case for any R&D team, whether or not it's on the roadmap. When several materials are sold under one ingredient name, how much does the name tell you? Enough to start a conversation. Nowhere near enough to choose a raw material, read a test result or sign off a substitution.
The name is moving faster than the definition
PDRN, short for polydeoxyribonucleotide, has traditionally meant a mixture of purified DNA fragments from salmon or trout reproductive tissue. What's now sold to cosmetic formulators covers a lot more ground. Cosmetic scientist Rinki Pramanik reviewed more than 50 PDRN technologies and finished products for Cosmetics Business this month. They spanned marine DNA, recombinant sequences, bacterial fermentation, microalgae and plant-derived nucleic acids, and her verdict is that they're "not biologically interchangeable."
Even that list mixes two kinds of information. "Plant-derived" tells you where a material came from, and "produced by fermentation" tells you how it was made. You need both. Even together, they don't describe what's in the drum.
None of this makes one route better than another. A sourcing claim can be true, and appealing on pack, while telling a formulator very little about the specification. So when two suppliers both call their ingredient PDRN, I'd ask each of them what they mean by the name, what they've measured and what they haven't.
A plausible mechanism is a reason to look, and no more
.png)
The evidence needs the same careful reading. Much of PDRN's scientific reputation, Pramanik notes, comes from pharmaceutical research involving injections or compromised tissue. She describes the mechanisms behind it (signaling through the adenosine A2A receptor, and cells reusing nucleotides through the salvage pathway) as proposed.
That line gets blurry once an ingredient reaches a consumer serum. In the launch round-up, aesthetic doctor Christine Hall says brands "cannot and should not claim that topical PDRN carries the same regenerative benefits as the injectable form." She adds that molecular characteristics, the delivery system and the other ingredients in the formula all matter.
So R&D has three separate questions. What does the published research suggest? What has been shown for this supplier's grade? And what happens when that grade goes into your product? Each answer is worth having, and none of them can stand in for another.
A study can give a team good reason to investigate an ingredient and still fall short of the claim marketing will eventually want to make. Speaking as a marketer, I'd much rather learn that early, from a note on the project record, than in final claims review. There's more on that hand-off in our post on cosmetic compliance data management.
Start the comparison with the supplier grade
In practice, that means building the comparison around the grade and treating the ingredient name as a label on top. I'd want each raw-material record to tie the supplier and trade name to the declared INCI, the biological source, the production route and whatever characterization exists. Depending on the material, that could include DNA content, fragment-size distribution, purity, carrier composition and the method behind each figure.
Those extra fields earn their place by stopping unlike materials from looking equivalent just because they share a column in a spreadsheet.
Concentration is usually where this bites first. The same round-up lists a Nip + Fab serum with "10%" in its name, while its PDRN content is given as 1%. Supplier grades raise that question one step earlier. Say a grade is sold as 1% PDRN in a carrier, and you use it at 4% in the formula. The finished product holds 0.04% PDRN. Record it as "4% PDRN" and the next person reads a figure a hundred times too high.
When a supplier's figure doesn't say whether it refers to the active or the supplied blend, leave that as an open question on the record. Standardizing a record shouldn't mean smoothing over what you don't know. The same goes when a supplier updates a specification or the team looks at a second source. The record should show what changed, even if the name on the drum hasn't. Passing a release spec is a separate question again, which we covered in when "within specification" isn't enough for an industrial-biotech ingredient.
Keep each result tied to its formulation
Once candidate grades reach the lab, the comparison gets harder, and more useful. A common base formulation is a sensible way to compare them. Suppliers often recommend their own use levels, processing conditions and delivery approaches, though, and those recommendations belong on the record next to the results, where the next person will find them. An email thread or a formulator's notebook won't do.
Skip that step and two questions blur together. Which grade performs better under the same conditions? And which performs best when it's made the way its supplier recommends? Both answers can inform a sourcing decision. They support different conclusions, and whoever reads the data six months later needs to know which one they're looking at.
When each result stays linked to the material, formulation, processing, packaging, storage and test method behind it, the next person can understand it without rebuilding the project from scratch.
Peptides and collagen raise the same questions
This year's example happens to be PDRN. The same questions apply to other biotech actives, peptides and collagen among them, as new sources and production routes reach the market. The ingredient name still does its job on labels and in an ingredient library. A development decision needs more: a clear account of the material, the conditions it was tested under and the evidence for its intended use.
For an innovation lead deciding whether PDRN belongs in the pipeline, its popularity justifies a closer look. Before you pick a grade, ask every supplier the same question: what exactly is in the drum, and how do you know?
How Uncountable approaches biotech actives
Uncountable's Research & Development suite keeps raw-material records, formulations, processing conditions and test results in one connected platform. A team comparing PDRN grades can see the supplier, source, specification and use level behind every result. When a supplier changes a specification, the change sits on the record next to the results that used the earlier version.
.png)
